English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/219271
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Effects of thioflavin T and GSK-3 inhibition on lifespan and motility in a Caenorhabditis elegans model of tauopathy

AuthorsGamir-Morralla, Andrea ; Sacristán, Sandra; Medina, Miguel ; Iglesias, Teresa
KeywordsAging
GSK-3
Alzheimer’s disease
C. elegans
Issue Date2019
PublisherIOS Press
CitationJournal of Alzheimer's Disease Reports 3(1): 47–57 (2019)
AbstractThe nematode Caenorhabditis elegans (C. elegans) is a powerful model organism to study lifespan and aging, protein aggregation, and neurodegeneration, as well as to carry out drug screenings. The C. elegans strain aex-3/T337 expresses human pathogenic V337M mutant tau under a pan-neuronal promoter and presents uncoordinated locomotion, accumulation of phosphorylated insoluble tau, and shortened lifespan. Herein we have used this strain to assay two compounds that could affect tau aggregation and/or phosphorylation, and looked for phenotypic changes in their lifespan and motility. The first compound is Thioflavin T (ThT), a member of the tetracycline family with protein antiaggregant properties, yet to be tested in a tauopathy model. The second is a novel small molecule, NP103, a highly selective inhibitor of glycogen synthase kinase-3 (GSK-3), the main kinase contributing to pathogenic tau hyperphosphorylation. Importantly, we find that ThT extends lifespan of aex-3/T337 worms as it does with control N2 animals, showing both strains similar locomotion features under this treatment. By contrast, NP103 improves the paralysis phenotype of aex-3/T337 mutants but not their lifespan. Our results show that both treatments present beneficial effects for this model of tauopathy and encourage pursuing further investigations on their therapeutic potential for AD and other tauopathies.
Publisher version (URL)https://doi.org/10.3233/ADR-180087
URIhttp://hdl.handle.net/10261/219271
DOIhttp://dx.doi.org/10.3233/ADR-180087
ISSN2542-4823
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
effectauo.pdf402,55 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.